Knee Disease, Osteo Arthritis Knee, Total Knee Arthroplasty, Total Knee Replacement
Conditions
Keywords
Knee Arthroplasty, Prosthesis, Implants, HLS implants, postero-stabilized prosthesis, third condyle, Arthroplasty
Brief summary
The purpose of this study is to evaluate clinical performance and safety in total knee arthroplasty using HLS implants.
Detailed description
It is planned to collect prospective and retrospective data from a continuous and exhaustive series of patients in a French center where Total Knee Arthroplasty with HLS prosthesis is performed routinely. All patients treated with HLS KneeTec (cemented, non-cemented or hybrid versions) implant will be included. All eligible patients seen in consultation and who agree to participate in the study should be included, systematically and consecutively, since the initiation of the study. Data will be collected retrospectively for HLS I, II, Evolution and Noetos® implants, and when prospectively for cementless, cemented and hybrid HLS KneeTec prosthesis. Post-surgery visit data will be collected at 1-y , 3-y , 5-y, 10-y FU visits per protocol then up to the latest FU visit available.
Interventions
Sponsors
Corin
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* For the HLS-1, HLS-2, HLS Evolution and HLS Noetos retrospective group: 1. Adult patients older than 18 years old. 2. Patients who have undergone routine preoperative clinical evaluations prior to their Total Knee Replacement surgery and implanted with one of the following prostheses from the HLS range: HLS-1, HLS-2, HLS Evolution and HLS Noetos between their first date of use in 1987 and their last date of use as normal practice at the participating site in accordance to indications and intended use as described in the Instruction for Use (IFU) of the study devices. 3. Patients who have been informed about their participation into an observational study. For the HLS KneeTec prospective group (with retrospective surgeries): 1. Adult patients older than 18 years old. 2. Patients who have undergone routine preoperative clinical evaluations and received a TKR or are suitable candidates for a TKR with a fixed or mobile postero-stabilized HLS KneeTec prosthesis (cementless, cemented or hybrid combination) for the treatment of a primary or secondary knee osteoarthritis and inflammatory disease such as rheumatoid arthritis in accordance to indications and intended use as described in the Instruction for Use (IFU) of the study devices. 3. Patients who are willing and able to complete the scheduled FU visits. 4. Patients who have been informed about their participation into an observational registry study
Exclusion criteria
* Patients mentally incompetent or unable to understand what participation in the study entails. * Patients who present signs and symptoms of any of the known contraindications described in the Instruction for Use (IFU) of the study devices. * Patients who deny their participation into the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of long-term survivorship of total knee replacement surgeries with HLS devices | 10-year | Implants survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of clinical performance | baseline (pre-surgery) to 10-year | Change of clinical performance using the International Knee Society (IKS) score |
| Evaluation of patient satisfaction with the surgery | time up to 10-year FU | Patients satisfaction post-surgery and any change during time up to 10-year FU using satisfaction questionnaire |
| Radiographic evaluation | baseline (1-year FU) to 10-year FU | Implant positioning and stability, presence/absence of progressive radiolucent lines around implant components, any sign of loosening components via radiological evaluation from baseline (1-year FU) to 10-year FU. |
| Evaluation of safety of the study implants | time up to 10-year FU | Number, severity and causal relationship of procedure or implant-related Adverse Events (AEs) starting intraoperatively up to 10-year FU. |
Countries
France
Outcome results
None listed